Business
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pi
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9LIPEL9jLECF3Yu.hIqHTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"text","content":"JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows:","length":300,"tagName":"p"},{"type":"text","content":"Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings.","length":131,"tagName":"p"},{"type":"text","content":"About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.","length":1074,"tagName":"p"},{"type":"text","content":"InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Infla...